<a href="https://www.medchemexpress.com/Istaroxime.html">Istaroxime</a>產(chǎn)品描述:Istaroxime is a potent inhibitor of <b>Na<sup>+</sup>,K<sup>+</sup>-ATPase</b> with <b>IC<sub>50</sub></b> of 0.11 μM.IC50 & Target: IC50: 0.11 μM (Na<sup>+</sup>,K<sup>+</sup>-ATPase)<sup>[1]</sup><i><b>In Vitro:</b></i> Istaroxime acting as a positive inotropic compound through the inhibition of the Na<sup>+</sup>,K<sup>+</sup>-ATPase<sup>[2]</sup>. Istaroxime (PST2744) inhibits the Na<sup>+</sup>/K<sup>+</sup>-ATPase activity from dog kidney with an IC<sub>50</sub> value of 0.43 ± 0.15 μM. Inhibition of Na<sup>+</sup>/K<sup>+</sup>-ATPase activity in preparations from guinea pig kidney yielded potencies of 8.5 μM for PST2744<sup>[3]</sup>.<i><b>In Vivo:</b></i> Istaroxime (PST2744) induces a progressive increase in +dP/dt<sub>max</sub> throughout the infusion that reaches 80% (ED<sub>80</sub>) at the cumulative dose of 1.89±0.37 mg/kg and a peak of 140±3.5% at the dose (ED<sub>max</sub>) of 4.88±0.6 mg/kg<sup>[3]</sup>.<br><br><br><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經(jīng)過多年努力已成為全球生物活性小分子領域的一流供應商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產(chǎn)品都進行嚴格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內(nèi)送達客戶;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產(chǎn)品提供免費試用裝;</span><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">已為全球多個知名企業(yè)、院校構(gòu)建各種定制型化合物庫。</span><br><br>產(chǎn)品鏈接:<a href="http://www.medchemexpress.cn/istaroxime.html">www.medchemexpress.cn/istaroxime.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
Istaroxime研究進展
發(fā)布日期:2017-10-31 瀏覽次數(shù):0
核心提示:a href=https://www.medchemexpress.com/Istaroxime.htmlIstaroxime/a產(chǎn)品描述:Istaroxime is a potent inhibitor of bNasup+/s
- 下一篇:暫無
- 上一篇:kobe2602研究進展
行業(yè)動態(tài)
更多...
- Istaroxime研究進展 10-31
- kobe2602研究進展 10-31
- Kobe0065研究進展 10-31
- NMS-859研究進展 10-31
- NMS-873研究進展 10-31
- AL 082D06研究進展 10-31
- LY2795050研究進展 10-31
- NS6180研究進展 10-31
- LH846研究進展 10-31
- QNZ46研究進展 10-31